PDF) Statins, Fibrates and Myopathy: Pathophysiological Mechanism, Risk Factors and Laboratory Markers

Statins, Fibrates and Myopathy: Pathophysiological Mechanism, Risk Factors and Laboratory Markers

Statin Myopathy.pdf

PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021

bok%3A978-1-4939-0515-7.pdf ?auth66=1397940469_51b8ba57efa3ddcad3f8aa303951bc25&ext=

JCM, Free Full-Text

Atherogenic dyslipidemia in Latin America: prevalence, causes and treatment. Consensus

JCM, Free Full-Text

Myopathy with statin-fibrate combination therapy: clinical considerations - Document - Gale OneFile: Health and Medicine

2018 Guidelines for the Management of Dyslipidemia in Korea

Improving Cardiovascular Risk Assessment to Optimize Therapy

PDF) Statins, Fibrates and Myopathy: Pathophysiological Mechanism, Risk Factors and Laboratory Markers

Muscle- and skeletal-related side-effects of statins: tip of the iceberg? - Johann Auer, Helmut Sinzinger, Barry Franklin, Robert Berent, 2016